Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FRANK MCGREW

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1922190396
CMS profile
314413
Location
MEMPHIS, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$13,899.93

174 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FRANK MCGREW

NPI 1922190396 · CMS profile ID 314413

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

MEMPHIS, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922190396?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FRANK MCGREW, NPI 1922190396, CMS profile ID 314413. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922190396?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). FRANK MCGREW, NPI 1922190396, CMS profile ID 314413. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922190396?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
FRANK MCGREW, NPI 1922190396, CMS profile ID 314413, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1922190396?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

174 matching records · $13,899.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 174 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 174.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Actelion Pharmaceuticals US, Inc. $19.7208/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078914063 CMS
E.R. Squibb & Sons, L.L.C. $21.4508/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101221090 CMS
Novartis Pharmaceuticals Corporation $25.2908/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087109804 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.4708/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118236316 CMS
Abbott Laboratories $19.0508/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125338952 CMS
Bayer Healthcare Pharmaceuticals Inc. $3.9508/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086095441 CMS
Bayer Healthcare Pharmaceuticals Inc. $24.3008/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086238418 CMS
Daxor Corporation $99.3508/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136815977 CMS
Novo Nordisk Inc $25.0007/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096628017 CMS
Novartis Pharmaceuticals Corporation $20.4907/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087109808 CMS
Janssen Pharmaceuticals, Inc $21.2807/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078186613 CMS
Novartis Pharmaceuticals Corporation $69.2807/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087109794 CMS
Actelion Pharmaceuticals US, Inc. $14.1707/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078914007 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.1607/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086158130 CMS
Medtronic, Inc. $108.8107/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119548305 CMS
Merck Sharp & Dohme LLC $17.9607/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141840960 CMS
Novartis Pharmaceuticals Corporation $29.4507/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087109802 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.4707/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118236312 CMS
Novartis Pharmaceuticals Corporation $6.3607/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087109806 CMS
ZOLL Circulation Inc $156.3207/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1067523727 CMS
AstraZeneca Pharmaceuticals LP $23.3807/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105804447 CMS
E.R. Squibb & Sons, L.L.C. $24.9907/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101221084 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.4307/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086255096 CMS
Esperion Therapeutics, Inc. $17.4507/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129446362 CMS
PFIZER INC. $20.8407/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131745580 CMS
Amgen Inc. $22.3607/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111648174 CMS
Bayer Healthcare Pharmaceuticals Inc. $2.5206/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086081482 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.5906/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086208625 CMS
AstraZeneca Pharmaceuticals LP $18.3906/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104213115 CMS
Novartis Pharmaceuticals Corporation $20.3506/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087109790 CMS
Amgen Inc. $2.0506/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117625654 CMS
Amgen Inc. $26.4406/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111648172 CMS
AstraZeneca Pharmaceuticals LP $50.9606/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105755725 CMS
Merck Sharp & Dohme LLC $19.1306/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141615160 CMS
Novo Nordisk Inc $25.0006/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096672480 CMS
Actelion Pharmaceuticals US, Inc. $18.8906/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078914191 CMS
Amgen Inc. $29.1405/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111648170 CMS
Alnylam Pharmaceuticals Inc. $14.7605/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125824237 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.6205/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086237798 CMS
Novartis Pharmaceuticals Corporation $15.9405/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087109788 CMS
Impulse Dynamics (USA) Inc. $182.8605/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100411159 CMS
PFIZER INC. $20.2105/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131526948 CMS
Impulse Dynamics (USA) Inc. $23.9505/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100411155 CMS
Medtronic, Inc. $112.2605/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119548303 CMS
AstraZeneca Pharmaceuticals LP $25.0305/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104533871 CMS
Novartis Pharmaceuticals Corporation $6.3805/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087109786 CMS
Merck Sharp & Dohme LLC $19.6105/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141615154 CMS
HEARTFLOW, INC. $15.6505/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154167648 CMS
Novartis Pharmaceuticals Corporation $30.6705/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087109770 CMS
Novartis Pharmaceuticals Corporation $9.3505/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087109772 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $38,310.26 271
PY2020 $8,172.44 73
PY2021 $8,531.98 140
PY2022 $19,406.69 213
PY2023 $17,431.29 204
PY2024 $13,899.93 174
PY2025 $13,423.03 162

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $226,782.19 49
PY2024 Principal investigator $264,716.33 70
PY2023 Principal investigator $285,486.35 59
PY2022 Principal investigator $182,112.19 93
PY2021 Principal investigator $232,448.15 130
PY2020 Principal investigator $312,107.86 119
PY2019 Principal investigator $505,872.05 145

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $518.40 12/05/2025 Non-covered Recipient Entity
The Stern Cardiovascular Foundation
SONATA-HCM No dispute reported 06/30/2026 1248068649
Principal investigator 1 Impulse Dynamics (USA) Inc. $270.00 12/01/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) No dispute reported 06/30/2026 1214122602
Principal investigator 1 Impulse Dynamics (USA) Inc. $840.00 12/01/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Assessment of Combined CCM and ICD Device in HFrEF (INTEGRA-D) No dispute reported 06/30/2026 1214122614
Principal investigator 1 Novartis Pharmaceuticals Corporation $53.46 11/15/2025 Non-covered Recipient Entity
THE STERN CARDIOVASCULAR CENTER
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190302905
Principal investigator 1 Impulse Dynamics (USA) Inc. $120.00 11/03/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) No dispute reported 06/30/2026 1214122604
Principal investigator 1 Impulse Dynamics (USA) Inc. $270.00 11/03/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Assessment of Combined CCM and ICD Device in HFrEF (INTEGRA-D) No dispute reported 06/30/2026 1214122616
Principal investigator 1 Amgen Inc. $4,875.46 10/28/2025 Non-covered Recipient Entity
STERN CARDIOVASCULAR FOUNDATION INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246648754
Principal investigator 1 CVRx, Inc. $12,804.00 10/28/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Not supplied No dispute reported 06/30/2026 1228698658
Principal investigator 1 Medtronic, Inc. $1,191.00 09/11/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319248
Principal investigator 1 Medtronic, Inc. $200.00 09/10/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319250
Principal investigator 1 Medtronic, Inc. $1,250.00 09/04/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319246
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,047.00 09/03/2025 Non-covered Recipient Entity
The Stern Cardiovascular Foundation
SONATA-HCM / Sotagliflozin / LX4211 No dispute reported 06/30/2026 1248067361
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,254.96 08/19/2025 Non-covered Recipient Entity
THE STERN CARDIOVASCULAR CENTER
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190302907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,125.00 08/01/2025 Non-covered Recipient Entity
STERN CARDIOVASCULAR FOUNDATION INC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215516169
Principal investigator 1 Alnylam Pharmaceuticals Inc. $700.00 08/01/2025 Non-covered Recipient Entity
STERN CARDIOVASCULAR FOUNDATION INC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215516172
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,300.00 08/01/2025 Non-covered Recipient Entity
STERN CARDIOVASCULAR FOUNDATION INC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215516176
Principal investigator 1 Impulse Dynamics (USA) Inc. $3,120.00 08/01/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) No dispute reported 06/30/2026 1214122596
Principal investigator 1 Medtronic, Inc. $343.00 08/01/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319244
Principal investigator 1 Medtronic, Inc. $1,026.00 07/30/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319242
Principal investigator 1 CVRx, Inc. $3,510.00 07/28/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Not supplied No dispute reported 06/30/2026 1228698654
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $192.00 07/09/2025 Non-covered Recipient Entity
The Stern Cardiovascular Foundation
SONATA-HCM / Sotagliflozin / LX4211 No dispute reported 06/30/2026 1248066951
Principal investigator 1 Medtronic, Inc. $4,444.00 07/09/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319240
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,879.00 06/23/2025 Non-covered Recipient Entity
The Stern Cardiovascular Foundation
SONATA-HCM No dispute reported 06/30/2026 1248066665
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $750.00 06/23/2025 Non-covered Recipient Entity
The Stern Cardiovascular Foundation
SONATA-HCM No dispute reported 06/30/2026 1248066667
Principal investigator 1 CVRx, Inc. $51,510.00 05/06/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Not supplied No dispute reported 06/30/2026 1228698660
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,683.80 04/30/2025 Non-covered Recipient Entity
The Stern Cardiovascular Foundation
SONATA-HCM / Sotagliflozin / LX4211 No dispute reported 06/30/2026 1248068181
Principal investigator 1 CVRx, Inc. $624.00 04/25/2025 Non-covered Recipient Entity
WCG IRB
Not supplied No dispute reported 06/30/2026 1228698770
Principal investigator 1 Amgen Inc. $6,995.00 04/23/2025 Non-covered Recipient Entity
STERN CARDIOVASCULAR FOUNDATION INC
The African American Heart Study: A Real-World Data Study of Atherosclerotic Cardiovascular Risk in African American and Black Participants in the US No dispute reported 06/30/2026 1246648762
Principal investigator 1 AstraZeneca UK Limited $20,425.00 04/14/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1185548155
Principal investigator 1 CVRx, Inc. $150.00 04/08/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Not supplied No dispute reported 06/30/2026 1228698650
Principal investigator 1 CVRx, Inc. $2,153.30 04/03/2025 Non-covered Recipient Entity
WCG IRB
Not supplied No dispute reported 06/30/2026 1228698836
Principal investigator 1 Impulse Dynamics (USA) Inc. $360.00 03/26/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) No dispute reported 06/30/2026 1214122598
Principal investigator 1 Medtronic, Inc. $5,500.00 03/12/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319238
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $15,000.00 03/07/2025 Non-covered Recipient Entity
The Stern Cardiovascular Foundation
SONATA-HCM / Sotagliflozin / LX4211 No dispute reported 06/30/2026 1248066783
Principal investigator 1 CVRx, Inc. $100.00 03/04/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Not supplied No dispute reported 06/30/2026 1228698648
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 03/03/2025 Non-covered Recipient Entity
STERN CARDIOVASCULAR FOUNDATION INC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215516159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,432.30 02/21/2025 Non-covered Recipient Entity
STERN CARDIOVASCULAR FOUNDATION INC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215516163
Principal investigator 1 Medtronic, Inc. $120.00 02/10/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319236
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,637.73 02/10/2025 Non-covered Recipient Entity
ADVANCED MED IMAGING NUCL
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190308052
Principal investigator 1 CVRx, Inc. $7,272.00 02/05/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Not supplied No dispute reported 06/30/2026 1228698656
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,682.12 01/28/2025 Non-covered Recipient Entity
THE STERN CARDIOVASCULAR FOUNDATION
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190307409
Principal investigator 1 CVRx, Inc. $550.00 01/27/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Not supplied No dispute reported 06/30/2026 1228698652
Principal investigator 1 Medtronic, Inc. $263.00 01/24/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
ALLEVIATE-HF No dispute reported 06/30/2026 1192319234
Principal investigator 1 Amgen Inc. $23,666.53 01/15/2025 Non-covered Recipient Entity
STERN CARDIOVASCULAR FOUNDATION INC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246648750
Principal investigator 1 Impulse Dynamics (USA) Inc. $1,040.00 01/15/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) No dispute reported 06/30/2026 1214122600
Principal investigator 1 Novartis Pharmaceuticals Corporation $533.03 01/15/2025 Non-covered Recipient Entity
THE STERN CARDIOVASCULAR CENTER
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190302909
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $6,956.10 01/14/2025 Non-covered Recipient Entity
The Stern Cardiovascular Foundation
SONATA-HCM / Sotagliflozin / LX4211 No dispute reported 06/30/2026 1248066249
Principal investigator 1 CVRx, Inc. $100.00 01/07/2025 Non-covered Recipient Entity
Stern Cardiovascular Foundation Inc
Not supplied No dispute reported 06/30/2026 1228698646
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,445.00 01/07/2025 Non-covered Recipient Entity
THE STERN CARDIOVASCULAR FOUNDATION
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190307413